Laboratory Industry Report   Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today's Diagnostic Lab Industry
  • Industry Trends, New Opportunities, and Emerging Competitive and Market Strategies
  • Comparative Data on Diagnostic Lab Test Pricing and Volumes
  • Analysis of the Impact of New and Proposed Legislation on Your Lab's Business
  • Industry Benchmarks to Gauge Your Lab Operations
  • Publicly-Held Lab Earnings Data and Performance Metrics
  • Industry Mergers, Acquisitions, and Partnerships
  • Lab Executives on the Move
  • And much more!
  • Find Out More about Laboratory Industry Report

Industry Trends
  • Strong Q4 as Lab Companies End Year with a Bang
  • Outlook for Medium-Size Labs Continues to Show Promise
  • Quarterly Numbers for Niche Labs Indicate a Maturing Market
  • High-Deductible Plans Tied to Reduced Use of Health Care, Including Diagnostic Testing
  • Some Labs Not Getting Paid for Molecular Assays; Result Is an Uncertain Future
  • Two Models for the Hospital Outreach Business: Dive In or Stay on Sidelines
  • Big Growth, Little Profit Is the Current Story for Esoteric Firms
  • Direct Release of Patient Tests: It’s Now Legal, But Is It Consumer Friendly?
  • Quest-Walmart, LabCorp-Walgreens Add Momentum to Mass Retailing of Lab Services
Capital & Investment
  • New Report Sheds Light on DX Tech Capital Flows
  • Quanterix Raises $46 Million to Fuel Expansion of Clinical Diagnostics
  • AltheaDX Raises $30 Million, Announces New Tests
  • Exosome Raises Second Round Funding, Close to Launching Cancer Tests
  • CardioDx Inks Draw Deal With Quest
  • Veracyte Obtains $40 Million in a Private Placement
Mergers & Acquisitions
  • Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month (Monthly Feature)
  • 2018 Shaping Up as Record Year for Healthcare Industry Mergers & Acquisitions
  • Most of the Smaller Players Have Been Absorbed, Leading to Fewer, But Bigger Deals
  • Laboratory M&A: A Shrinking Window of Opportunity
  • XIFIN Acquired by Private Equity Firm
  • Genova Diagnostics Purchased by Los Angeles Equity Firm
  • Hologic Sells Blood Screening Business
  • Laboratory M&A Heating Up Again—On a Smaller Scale
  • 2017: The Year in DX Mergers & Acquisitions
Business Strategy
  • NeoGenomics Financial Success Achieved With Microscopic Attention to Detail
  • Quest’s Latest Acquisition Expected to Help Boost Bottom Line
  • Two Pathology Practices, Two Routes to the Future
  • Sleep Apnea Assay Could Be Groundbreaker in Marketing and Branding
  • New Lab Venture Is Direct Descendant of deCODE Genetics
  • Strategic Alliances Promote Test Access and Development
Competitive Market Activity
  • The Dx Pipeline: A Roundup of the Month’s Key New Product Launches (Monthly Feature)
  • LabCorp Launches New Division to Focus On NGS Testing
  • 23andMe Continues to Spearhead Direct-to-Consumer Marketing of LDT Genetic Tests
  • Illumina Launches an Incubator for Genomic Startups
  • Aurora at a Crossroads: Looking to Grow or Change
  • Ailing Domestically, Quest Diagnostics Makes Major Move in India
  • Quest Diagnostics Unveils a Pair of Personalized Medicine Blockbusters
  • Through Deals and an Executive Revamp, Aurora Diagnostics Strains Toward the Black
  • Theranos & Its CEO Settle Stock Fraud Charges with SEC
Growth Trends & Opportunities
  • More Labs Turning to Data Analytics To Improve Operations and Population Health
  • Ordering Physicians: Oncologists Say Genomic Testing Is Overhyped
  • Emerging Tests: Medicare to Cover Next Gen-Sequencing Tests for Advanced Cancer
  • Outreach Survey Focuses on Clinical Laboratory Industry Trends Amidst Greatest Disruption in Three Decades
  • Two More Zika Tests Get Emergency Use Authorization
Lab Management
  • Diagnostic Danger in the Lab: Time to Reform How We Process Orders
  • Out of Network: 6 Frequently Asked Questions
  • Lean Six Sigma is Not Quality
  • Study Casts Doubt on Cost-Effectiveness of Leading Breast Cancer Recurrence Assay
  • Safety Lapses Continue with Select Agents
  • Should You Be Paying Your Staff Overtime?
  • Outreach Labs Remain Profitable Despite Antiquated Systems & Lack of Exec Respect
  • Employment Law Update for Lab Managers
  • Don’t Crash & Burn: Why Cutting Your Quality Department’s Budget is not a Good Idea
Legal & Regulatory News
  • PAMA-geddon: Lab Industry Asks Court to Stop New Medicare Fee Schedule
  • Medicare Reimbursement: 4 Molecular Assays Score Big Coverage Wins
  • FDA Watch: New Policy Would Allow DTC Marketing of Genetic Tests without Premarket Approval
  • New Laws: Congress Doubles Penalties for Medicare Fraud & Abuse
  • FDA Watch: Why the New NGS Guidance May Be a Paper Tiger
  • FDA Watch: Off-Label Marketing Rule Put Back on Ice & Extra Comment Time for CLIA Waiver Proposals
  • FDA Watch: Greenlights for NGS Tumor Panels May Augur New Approach to LDT Approvals—Both Product & Pathway
Join Now
Laboratory Industry Report 888-729-2315